Argos Therapeutics Opens Registration for Upcoming Investor Day
December 01, 2016 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium
November 29, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Cellthera Presents Preclinical Data at SITC Using Argos’ Individualized Immunotherapy
November 18, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 18, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Participating in Strategies for an HIV Cure 2016 Meeting
November 14, 2016 09:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
November 14, 2016 06:30 ET
|
Argos Therapeutics Inc.
- Dr. Richard D. Katz Joined as Chief Financial Officer -- Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV --...
Argos Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Participate in SITC 2016 Annual Meeting
November 10, 2016 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics to Host Third Quarter 2016 Financial Results Conference Call on Monday, November 14, 2016
November 07, 2016 08:30 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
Argos Therapeutics Announces Publication of a Case Report on Long-term Survival of Kidney Cancer Patients Treated with AGS-003 Individualized Immunotherapy Featured in the Kidney Cancer Journal
November 03, 2016 08:55 ET
|
Argos Therapeutics Inc.
Two advanced kidney cancer patients from a Phase 2 clinical trial maintain ongoing control of metastatic disease seven years after initiation of treatment with AGS-003 in combination with sunitinib....
Argos Therapeutics Participating in 4th International mRNA Health Conference
November 02, 2016 08:00 ET
|
Argos Therapeutics Inc.
DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...